PFS results were supported by the secondary end point of overall survival , with an ITT HR of 1.28 ( 95 % CI , 0.95 to 1.72 ; P = .11 ) ; in patients with centrally confirmed HER2-positive tumors , the HR was 1.47 ( 95 % CI , 1.03 to 2.09 ; P = .03 ) .